1. Home
  2. TACT vs ATOS Comparison

TACT vs ATOS Comparison

Compare TACT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$4.88

Market Cap

35.7M

Sector

Technology

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$2.19

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
ATOS
Founded
1996
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.7M
36.2M
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
TACT
ATOS
Price
$4.88
$2.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$23.00
AVG Volume (30 Days)
21.9K
105.0K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
87.88
N/A
EPS
0.07
N/A
Revenue
N/A
$1,758.00
Revenue This Year
$10.36
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$70.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$0.53
52 Week High
$6.02
$7.56

Technical Indicators

Market Signals
Indicator
TACT
ATOS
Relative Strength Index (RSI) 44.70 40.89
Support Level $4.62 $0.58
Resistance Level $5.48 $2.60
Average True Range (ATR) 0.26 0.17
MACD -0.06 0.07
Stochastic Oscillator 12.98 25.64

Price Performance

Historical Comparison
TACT
ATOS

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: